Alpha Capital Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Alpha Capital Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$3.73M	Sell	4,828 -565	-10%	-$433K	0.54%	57
2025 Q4	$4.16M	Sell	5,393 -119	-2%	-$80.8K	0.59%	57
2025 Q3	$3.1M	Buy	5,512 +36	+0.7%	+$20.4K	0.49%	64
2025 Q2	$2.87M	Buy	5,476 +1,966	+56%	+$1.1M	0.5%	64
2025 Q1	$2.23M	Buy	3,510 +363	+12%	+$250K	0.42%	68
2024 Q4	$2.24M	Buy	3,147 +1,912	+155%	+$1.6M	0.41%	67
2024 Q3	$1.3M	Buy	+1,235	New	+$1.37M	0.24%	69
2021 Q1	–	Sell	-554	Closed	-$268K	–	118
2020 Q4	$268K	Sell	554 -570	-51%	-$308K	0.07%	99
2020 Q3	$629K	Buy	1,124 +671	+148%	+$407K	0.18%	79
2020 Q2	$283K	Buy	+453	New	+$257K	0.1%	91

Other funds holding REGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Alpha Capital Management's REGN Position: Q1 2026 in Review

Alpha Capital Management reduced its Regeneron Pharmaceuticals (REGN) stake by 10% in Q1 2026, selling an estimated $433K and leaving 4,828 shares worth $3.73M. The position accounts for 0.54% of the portfolio, ranked #57.

Alpha Capital Management first reported a position in REGN in Q2 2020 and has held it in 10 quarters since. The position peaked at $4.16M in Q4 2025. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

Alpha Capital Management held 4,828 shares of Regeneron Pharmaceuticals worth $3.73M as of Q1 2026.
Alpha Capital Management sold 565 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $433K.
Regeneron Pharmaceuticals made up 0.54% of Alpha Capital Management's portfolio in Q1 2026, its #57 holding.
Alpha Capital Management first reported a position in Regeneron Pharmaceuticals in Q2 2020 and has held it in 10 quarters since.
Alpha Capital Management's Regeneron Pharmaceuticals position peaked at $4.16M in Q4 2025.
1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Alpha Capital Management's 13F filing for Q1 2026, filed 13 May 2026.